We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Federal Circuit Reverses Priority In Claritin Battle

Law360 (February 6, 2006, 12:00 AM EST) -- In a protracted patent interference case, a pharmaceutical company hoping to trump its rival’s patent for making Claritin’s active ingredient has lost once again at the U.S. Court of Appeals for the Federal Circuit, after its inventors’ testimony was discredited by document backdating.

The duel between the two Spanish companies began in May 2002, when Medichem SA sued rival Rolabo SL to establish priority over a process for making loratadine, the active ingredient in the popular allergy drug Claritin. Medichem sought to trump Rolabo’s priority date...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.